Skip to main content

DENTCA

ApplicationTorrance, California, USAFounded 2007· One of 686 Application companies tracked by AMPulse

Develops CAD/CAM denture technology and 3D printing solutions for high-quality dental prosthetic production.

CEO / Founder
Tae Hyung Kim (President)
Team Size
1-10
Stage
Active
Total Funding
$8.65M
Key Investors
Mitsui Chemicals, Inc.

Technology & Products

Key Products

CAD/CAM denture technology, 3D printable denture base material, TrueDent-D Resin, web-based denture design platform.

Technological Advantage

Proprietary CAD/CAM design combined with FDA-cleared Class II 3D printing materials compatible with Carbon 3D hardware.

Patent position

DENTCA has filed 12 patent families in total, compared with Kulzer’s 26. AMPulse analysis

Filing momentum
0 families filed 2022–2024, 3 in 2019–2021
Filed in
US 42%WO 25%CN 17%EP 17%
Named competitors, AM patent families
Kulzer 26

12 AM patent families in total. Recent years are still being published, so read a filing change against the same-office figure.

Differentiation

Value Proposition

Reduces denture production to a two-visit workflow by capturing impression, vertical dimension, and centric relation in a single one-hour visit.

How They Differentiate

Pioneer of CAD/CAM dentures; first to receive Pride Institute's Best-of-Class Technology Award in the denture category.

Market & Competition

Target Customers

Dental professionals, dental labs, and dental schools.

Industry Verticals

Dental prosthetics; Medical

Competitors

Kulzer GmbH

Growth & Milestones

Growth Metrics

Annual revenue of $5.2 million in 2024.

Major Milestones

2012: Pride Institute's Best-of-Class Technology Award; 2013: Mitsui Chemicals acquired 50.01% stake; 2015: Townie Choice Awards; 2015: The Dental Advisor - Top Innovative Product

Notable Customers

Aspen Dental; Carbon; Mitsui Chemicals

https://www.dentca.com

AM patents

AM-relevant patents linked to this company.

Patents
13
Granted
5
Families
12

Leading domains: application (12), process (8), material (6)

Filings by year: 2021: 3 · 2017: 1 · 2016: 1 · 2014: 3 · 2013: 2 · 2012: 2

  1. Photo-curable resin compositions and method of using the same in three-dimensional printing for manufacturing artificial teeth and denture base110423311 · CN
  2. PHOTO-CURABLE RESIN COMPOSITIONS AND METHOD OF USING THE SAME IN THREE-DIMENSIONAL PRINTING FOR MANUFACTURING ARTIFICIAL TEETH AND DENTURE BASE2986654 · EP
  3. PHOTO-CURABLE RESIN COMPOSITIONS AND METHOD OF USING THE SAME IN THREE-DIMENSIONAL PRINTING FOR MANUFACTURING ARTIFICIAL TEETH AND DENTURE BASE2014098956 · WO
  4. Method and apparatus for preparing removable dental prosthesis9675432 · US
  5. PHOTO-CURABLE RESIN COMPOSITIONS CONTAINING IMPACT MODIFIER FOR THREE DIMENSIONAL PRINTING AND CURED DENTAL PRODUCT MADE OF THE SAME4312944 · EP

Funding rounds

  • Corporate Majority50.01% stake2013-06

Why this company matters

AMPulse analysis, not a company disclosure

DENTCA is a Los Angeles-based pioneer in CAD/CAM denture technology, established in 2007 to digitize a traditionally analog and multi-visit prosthetic workflow. Its core innovation is a two-visit clinical process that captures impression, vertical dimension, and centric relation in a single one-hour appointment, enabled by the patented EZ-Tracer tray system. This contrasts with conventional denture fabrication requiring four or more appointments and extensive manual laboratory steps.

The company's technology stack combines proprietary CAD/CAM design software with FDA-cleared Class II photopolymer resins, including TrueDent-D Resin, for use on Carbon 3D hardware via VPP-CDLP (vat photopolymerization continuous digital light processing). DENTCA also offers a web-based denture design platform that streamlines case submission and collaboration between dental professionals and labs. The materials are photo-curable resin compositions with impact modifiers, protected by a patent granted in 2023.

Target customers include dental professionals, dental labs, and dental schools. Notable partners include Aspen Dental, Carbon, and Mitsui Chemicals, which acquired a 50.01% stake in 2013 and now holds majority ownership. DENTCA reported annual revenue of $5.2 million in 2024 and has raised $8.65 million in total funding. The company received the Pride Institute's Best-of-Class Technology Award in 2012 and the Dental Advisor's Top Innovative Product award in 2015.

DENTCA's strategic moat lies in its first-mover position in CAD/CAM dentures, proprietary clinical workflow, and integration with Carbon's hardware ecosystem. The primary competitive risk is the emergence of alternative digital denture platforms from established dental materials firms such as Kulzer GmbH, which could erode DENTCA's differentiation in a market where speed and accuracy are increasingly table stakes.